ArticleCureus2025
Evaluation of the Incidence of Malignancy in Sjögren's Syndrome: A Single-Center Study From Turkey.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Late-Onset Sjögren disease: A different clinical entity?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSjögren's syndrome (SS) is known to be associated with an elevated cancer incidence. This study aimed to ascertain SS patients' cancer incidence rates and risk variables at a single center in Turkey.
methodsThe clinical data of SS patients were analyzed retrospectively. Cancer incidences for the overall population were obtained. The standardized incidence rates (SIRs) of hematological and solid cancers were calculated in comparison with the overall population.
resultsThe study included 303 SS patients, of whom 27 (8.9%) were diagnosed with cancer. Twenty-one solid (6.9%) and six (2%) hematologic cancers were identified. The SIR for all cancers was 2.25 (95% confidence interval (CI) 1.513-3.228). The SIR for hematologic cancers was 7.22 (95% CI 2.93-5.04), while the SIR for non-Hodgkin lymphoma (NHL), the most prevalent malignancy, was 11.76 (95% CI 3.73-28.38). The most prevalent malignancies were papillary thyroid and breast cancers, with a SIR of 3.04 (95% CI 1.937-4.58) for solid cancers. The SIR for both papillary thyroid and breast cancers was 8.43 (95% CI 3.689-16.68) and 1.85 (95% CI 0.687-4.105), respectively. A higher risk has also been linked to the presence of lymphopenia.
conclusionSS patients exhibit an increased risk of both solid and hematologic malignancies compared to the total population. This study reveals an increased risk of NHL and thyroid cancer in the Turkish population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.